image header

Investor Overview

Investor Overview

ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Our lead candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated proprietary Fc domain. We have developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities.

ALX Oncology


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

Sep 17, 2020

ALX Oncology Added to Russell 2000® and 3000® Indexes Read more

Sep 8, 2020

ALX Oncology Announces Participation at Upcoming Investor Conferences Read more

Aug 27, 2020

ALX Oncology Reports Second Quarter 2020 Financial Results and Provides Operational and Clinical Highlights Read more